

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Lu-99A

RRID:CVCL_1393

Type: Cell Line

Proper Citation

RRID:CVCL_1393

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1393

Proper Citation: RRID:CVCL_1393

Description: Cell line Lu-99A is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung giant cell carcinoma

Defining Citation: [PMID:10536175](#), [PMID:15746151](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35839778](#)

Comments: Population: Japanese and Korean., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Lu-99A

Synonyms: LU-99A, Lu99A, LU99A

Cross References: CLO:CLO_0037028, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:937, cancercellines:CVCL_1393, Cell_Model_Passport:SIDM01219, CGH-DB:198-1, CGH-DB:9187-4, ChEMBL-Cells:ChEMBL3308757, ChEMBL-Targets:ChEMBL1075493, Cosmic:889094, Cosmic:907796, Cosmic:917980, Cosmic:932925, Cosmic:1066165, Cosmic:1239919, Cosmic:1995498, Cosmic:2668334, Cosmic-CLP:907796, DepMap:ACH-002158, EGA:EGAS00001000978, GDSC:907796, GEO:GSM827578, GEO:GSM1670068,

IARC_TP53:21482, JCRB:JCRB0044, LINCS_LDP:LCL-1908,
Pharmacodb:LU99A_870_2019, PRIDE:PXD030304, Progenetix:CVCL_1393,
PubChem_Cell_line:CVCL_1393, Wikidata:Q54903212

ID: CVCL_1393

Hierarchy: cvcl_3015

Record Creation Time: 20220427T220737+0000

Record Last Update: 20260913T004758+0000

Ratings and Alerts

No rating or validation information has been found for Lu-99A.

No alerts have been found for Lu-99A.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Janes MR, et al. (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell, 172(3), 578.